FDA Grants Breakthrough Device Designation to Cleo Skin AI Pathology Tool
Clinical studies found improved melanoma detection sensitivity, while a small US evaluation showed a 20% reduction in slide analysis time.
Clinical studies found improved melanoma detection sensitivity, while a small US evaluation showed a 20% reduction in slide analysis time.
A new Pennsylvania law will require state-regulated insurers and Medicaid to cover blood-based colorectal cancer screening tests with no cost-sharing, Dec 21, 2026.
Hologic has agreed to acquire Reveal Genomics, adding the HER2DX assay to its oncology diagnostics portfolio and expanding genomic testing options for breast cancer, according to a company statement.
Guardant Health will present 25 abstracts at ESMO 2026, highlighting new data on ctDNA liquid biopsy for cancer monitoring, including MRD surveillance and therapy resistance in lung, colorectal, and gastric cancers.New research examines how circulating tumor DNA testing could help detect cancer recurrence, track treatment response, and identify resistance across multiple cancer types.
Read MoreA study of more than 60,000 lung cancer cases found that AI could predict the presence of 12 biomarkers with more than 80% sensitivity, potentially helping laboratories prioritize additional testing.
Read MoreBiodesix and Vanderbilt have partnered to develop an AI-powered lung cancer risk test that combines blood-based and imaging biomarkers, with initial data to be presented at RSNA 2026 and commercial launch targeted for 2028.
Read MoreSOPHiA GENETICS and Myriad Genetics are collaborating to develop a decentralized prostate cancer companion diagnostic, aiming to enable local labs to assess DNA repair deficiencies using the PrGIS biomarker in clinical trials.
Read MoreKeck Medicine of USC has launched a phase 1 trial to assess whether a liquid biopsy detecting rare cells and extracellular vesicles can help identify early-stage breast cancer alongside standard mammography.
Read MoreAignostics has launched HETA Clinical, an AI-based suite for digital pathology that analyzes whole-slide H&E images to assess tumor content and tissue quality, aiming to reduce molecular test failure rates in clinical labs.
Read MoreA modeling study presented at ACG 2026 projects that blood-based colorectal cancer screening averts more deaths and increases colonoscopy completion rates compared to stool-based methods, according to data from Guardant Health.
Read MoreThe DNA-based test showed 96.8% specificity in cervical samples and could help physicians determine which patients need further testing for endometrial cancer.
Read MoreBiodesix presented data at CHEST 2026 from over 2,000 patients in the CLARIFY study, highlighting how Nodify Lung blood-based testing integrates with PET imaging to improve follow-up adherence for pulmonary nodules.
Read MoreAnalyzing the structure of existing biomarkers could reveal new information about cancer, helping laboratories deliver more accurate and clinically useful results.
Read MoreCastle Biosciences’ new data presented at ACG 2026 show the TissueCypher test offers objective risk stratification for Barrett’s esophagus progression, providing information beyond standard histopathology.
Read MoreIMS Solutions, a University of Birmingham and Imperial College London spin-out, has raised £1.1 million to commercialize mass spectrometry-based steroid biomarker tests for adrenal cancer and PMOS, with clinical validation underway.
Read MoreNew data show high diagnostic performance for ovarian, endometrial, and cervical cancers, with a targeted assay designed to run on existing clinical laboratory equipment.
Read MoreAn independent validation study of 426 patients evaluated the assay’s ability to assess 10-year recurrence risk and identify patients more likely to benefit from radiation therapy.
Read More10x Genomics and Fred Hutchinson Cancer Center have launched a multi-project collaboration to study single cell and spatial profiling for cancer diagnostics, including biomarkers in bladder cancer and residual disease detection in AML.
Read More